Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tandem Diabetes Care (TNDM) EBITDA Margin (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed EBITDA Margin for 13 consecutive years, with 7.9% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin rose 969.0% year-over-year to 7.9%, compared with a TTM value of 27.3% through Dec 2025, down 1673.0%, and an annual FY2025 reading of 2493.61%, up 250418.0% over the prior year.
  • EBITDA Margin was 7.9% for Q4 2025 at Tandem Diabetes Care, up from 7.92% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 7.9% in Q4 2025 and bottomed at 72.11% in Q1 2023.
  • Average EBITDA Margin over 5 years is 14.29%, with a median of 8.94% recorded in 2022.
  • The sharpest move saw EBITDA Margin plummeted -6236bps in 2023, then surged 4863bps in 2024.
  • Year by year, EBITDA Margin stood at 4.85% in 2021, then tumbled by -218bps to 5.72% in 2022, then tumbled by -135bps to 13.43% in 2023, then surged by 87bps to 1.79% in 2024, then surged by 541bps to 7.9% in 2025.
  • Business Quant data shows EBITDA Margin for TNDM at 7.9% in Q4 2025, 7.92% in Q3 2025, and 20.25% in Q2 2025.